| Description |
Callophycin A, red seaweed derived metabolite, is potently against C. albicans. Callophycin A exhibits potent activity against drug resistance vaginal candidiasis[1].
|
| Related Catalog |
|
| Target |
MIC: 62.5~250 mg/L (Candida albicans)[1]
|
| In Vivo |
Callophycin A (1%; for 5 days) dramatically reduces CFU of Candida albicans; and significantly reduces the amount of IL-6, IL-12, IL-17 and IL-22 compared with disease control group[1]. Animal Model: Female Swiss albino mice (infected with Candida albicans)[1] Dosage: 1% Administration: For 5 days Result: Dramatically reduces CFU of Candida albicans from about 400 to 100/ml; and significantly (p < 0.001) reduces the amount of IL-6 (2.71 ± 0.09 to 1.83 ± 0.03 pg/µl), IL-12 (7.33 ± 0.15 to 6.13 ± 0.15 pg/µl), IL-17 (17.83 ± 0.21 to 13.70 ± 0.2 pg/µl) and IL-22 (5.33 ± 0.25 to 4.20 ± 0.26 pg/µl) compared with disease control group.
|
| References |
[1]. Arumugam Ganeshkumar, et al. New insight of red seaweed derived Callophycin A as an alternative strategy to treat drug resistance vaginal candidiasis. Bioorg Chem. 2020 Nov;104:104256.
|
